In the current study, we observed that Lm-LLO-E7 increases the total CD8+ effector T cell infiltration into the tumor, which is further significantly amplified by addition of agonist anti-GITR Ab (***P ≤ 0.001) (Fig. 3a). The gene discussed is TNFRSF18; the disease is neoplasm.